| Pegasys (pegylated interferon α -2a) / Roche |
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | Chonic hepatitis HCV-related | | | | |
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients |
|
|
| Ongoing | 4 | 230 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Miguel Santin Cerezales | Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels | | | | |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon |
|
|
| Ongoing | 3 | 50 | Europe | KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS | OSPEDALE S. RAFFAELE | patients affected by HIV and chronic HCV or compensated cirrhosis | | | | |
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ |
|
|
| Ongoing | 3 | 60 | Europe | KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS | OSPEDALE S. RAFFAELE | PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES | | | | |
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1. |
|
|
| Ongoing | 3 | 414 | Europe | Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus | Charité Universitätsmedizin Berlin | First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV | | | | |
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy |
|
|
| Completed | 1/2 | 17 | US | Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys | Massachusetts General Hospital, Novartis, Genentech, Inc. | HIV Infection | 08/22 | 12/23 | | |
